Disorders of the blood and blood forming tissues.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Surgical procedure involving either partial or entire removal of the spleen.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY. If appropriate, biopsy or surgery can be performed during laparoscopy.
Enlargement of the spleen.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans.
Infections with bacteria of the genus KLEBSIELLA.
Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins.
Substances that reduce the growth or reproduction of BACTERIA.
A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Proteins found in any species of bacterium.

Changes in haematological parameters and iron metabolism associated with a 1600 kilometre ultramarathon. (1/1031)

OBJECTIVE: To investigate haematological variations and iron related changes in the serum of participants in a 1600 kilometre ultramarathon run. PARTICIPANTS: Seven male and two female participants in a 1600 km foot race. METHODS: Blood samples were obtained from the participants before, after four and 11 days of running, and at the end of the event. Samples were analysed by standard methods for haemoglobin, packed cell volume, total red cell count, mean red cell volume, mean red cell haemoglobin, total white cell count and differential, platelets, reticulocytes, iron, ferritin, total iron binding capacity, percentage transferrin saturation, haptoglobin, and bilirubin and corrected for changes in plasma volume. RESULTS: The following variables decreased during the event (p < 0.05): haemoglobin, packed cell volume, mean red cell volume, percentage lymphocytes, percentage monocytes, serum iron, total iron binding capacity, and percentage transferrin saturation. Increases (p < 0.05) were found in plasma volume, total red cell count (day 4 only), total white cell count, percentage and absolute numbers of neutrophils and reticulocytes, absolute numbers of lymphocytes and monocytes (day 4 only), absolute numbers of eosinophils (day 11 and race end), absolute numbers of basophils (race end only), platelets, ferritin, haptoglobin, and bilirubin (day 4 only). CONCLUSION: Ultramarathon running is associated with a wide range of changes in haematological parameters, many of which are related to the normal acute phase response to injury. These should not be confused with indicators of disease.  (+info)

Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. (2/1031)

PURPOSE: To evaluate the activity and toxicity of the combination of cisplatin (80 mg/m2 day 1) and vinorelbine (25 mg/m2 days 1 and 8) in patients with carcinoma of the uterine cervix that has not been previously treated with chemotherapy. PATIENTS AND METHODS: Fifty patients with cervical cancer were enrolled onto this study (27 stage IB-III, 23 stage IVB-recurrent). A two-stage optimal Simon design was applied. Thirteen responders of 29 treated patients were required to proceed beyond the first stage, and 28 responders were needed overall. RESULTS: Hematologic toxicity was mild, with neutropenia being the most frequent side effect. Nonhematologic toxicity was frequent but never severe; one patient had grade 3 peripheral neurotoxicity. Objective responses were recorded for 32 patients (64%): 11 patients (22%) achieved a complete response (CR) and 21 patients (42%) achieved a partial response (PR). The response rate was 81.5% in patients with IB-III stage (25.9% CR rate) and 43.5% in patients with IVB-recurrent disease (17.4% CR rate). Responses were seen both in stage IVB patients (one CR and two PRs, for an overall rate of 37.5%) and in patients with recurrent disease (three CRs + four PRs, for an overall rate of 46.7%). CONCLUSION: The combination of cisplatin and vinorelbine is an active regimen in the treatment of patients with early-stage and advanced carcinoma of the uterine cervix. The hematologic and nonhematologic toxicity of this combination is mild.  (+info)

Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. (3/1031)

PURPOSE: Both paclitaxel and cisplatin have moderate activity in patients with metastatic or recurrent cancer of the cervix, and the combination of these two agents has shown activity and possible synergism in a variety of solid tumors. We administered this combination to patients with metastatic or recurrent cervical cancer to evaluate its activity. PATIENTS AND METHODS: Thirty-four consecutive patients were treated on an outpatient basis with paclitaxel 175 mg/m2 administered intravenously over a 3-hour period followed by cisplatin 75 mg/m2 administered intravenously with granulocyte colony-stimulating factor support. The chemotherapy was administered every 3 weeks for a maximum of six courses. RESULTS: Sixteen patients (47%; 95% confidence interval, 30% to 65%) achieved an objective response, including five complete responses and 11 partial responses. Responses occurred in 28% of patients with disease within the radiation field only and in 57% of patients with disease involving other sites. The median duration of response was 5.5 months, and the median times to progression and survival for all patients were 5 and 9 months, respectively. Grade 3 or 4 toxicities included anemia in 18% of patients and granulocytopenia in 15% of patients. Fifty-three percent of patients developed some degree of neurotoxicity; 21% of cases were grade 2 or worse. CONCLUSION: The combination of paclitaxel with cisplatin seems relatively well tolerated and moderately active in patients with metastatic or recurrent cervical cancer. The significant incidence of neurotoxicity is of concern, and alternative methods of administration of the two agents could be evaluated. Then, further study of this combination, alone or with the addition of other active agents, is warranted.  (+info)

Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. (4/1031)

PURPOSE: To evaluate the efficacy and tolerance of combined irinotecan and oxaliplatin in patients with advanced colorectal cancer pretreated with leucovorin-modulated fluoropyrimidines. PATIENTS AND METHODS: Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within 6 months after discontinuing palliative chemotherapy with fluoropyrimidines/leucovorin, were enrolled onto this study. Treatment consisted of oxaliplatin 85 mg/m2 on days 1 + 15 and irinotecan 80 mg/m2 on days 1 + 8 + 15 every 4 weeks. Depending on the absolute neutrophil counts (ANC) on the day of scheduled chemotherapeutic drug administration, a 5-day course of granulocyte colony-stimulating factor (G-CSF) 5 microg/kg/d was given. RESULTS: The overall response rate was 42% for all 36 assessable patients (95% confidence interval, 26% to 59%), including two complete remissions (6%). Thirteen additional patients (36%) had stable disease, and only eight (22%) progressed. The median time to treatment failure was 7.5 months (range, 1 to 13.5+ months). After a median follow-up time of 14 months, 19 patients (53%) are still alive. Hematologic toxicity was commonly observed, although according to the ANC-adapted use of G-CSF (in 31 patients during 81 of 174 courses), it was generally mild: grade 3 and 4 granulocytopenia occurred in only five and two cases, respectively. The most frequent nonhematologic adverse reactions were nausea/emesis and diarrhea, which were rated severe in 17% and 19%, respectively. CONCLUSION: Our data suggest that the combination of irinotecan and oxaliplatin with or without G-CSF has substantial antitumor activity in patients with progressive fluoropyrimidine/leucovorin-pretreated colorectal cancer. Overall toxicity was modest, with gastrointestinal symptoms constituting the dose-limiting side effects. Further evaluation of this regimen seems warranted.  (+info)

Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. (5/1031)

PURPOSE: To evaluate the tolerance and efficacy of the combination of docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Fifty-one chemotherapy-naive patients with NSCLC were treated with gemcitabine 900 mg/m2 intravenously on days 1 and 8 and docetaxel 100 mg/m2 intravenously on day 8 with granulocyte colony-stimulating factor (150 microg/m2, subcutaneously) support from day 9 to day 15. Treatment was repeated every 3 weeks. RESULTS: The patients' median age was 64 years. The World Health Organization performance status was 0 to 1 in 39 patients and 2 in 12 patients. Fifteen patients (29%) had stage IIIB disease, and 36 (71%) had stage IV; histology was mainly squamous cell carcinoma (59%). A partial response was achieved in 19 patients (37.5%; 95% confidence interval, 24% to 50%); stable disease and progressive disease were each observed in 16 patients (31.4%). The median duration of response and the time to tumor progression were 5 and 6 months, respectively. The median survival was 13 months, and the actuarial 1-year survival was 50.7%. Grade 4 anemia and thrombocytopenia were rare (2%). Four patients (8%) developed grade 3 or 4 neutropenia, and all were complicated with fever; there was no treatment-related death. Grade 3 or 4 diarrhea occurred in three patients (6%), grade 2 or 3 neurotoxicity in four patients (8%), grade 2 or 3 asthenia in 10 patients (20%), and grade 2 or 3 edema in 10 patients (20%). CONCLUSION: The combination of docetaxel/gemcitabine is well tolerated, can be used for outpatients, and is active for the treatment of advanced NSCLC. This treatment merits further comparison with other cisplatin- or carboplatin-based combinations.  (+info)

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. (6/1031)

PURPOSE: To evaluate the efficacy of paclitaxel and carboplatin (PC) in small-cell lung cancer (SCLC) patients resistant to cyclophosphamide, doxorubicin, and etoposide (CDE). PATIENTS AND METHODS: We performed a phase II study with PC in SCLC patients who relapsed within 3 months after first-line treatment with CDE. Paclitaxel administration (175 mg/m2 by a 3-hour intravenous infusion) was followed by a 30-minute infusion of carboplatin (area under the curve 7; Chatelut formula) once every 3 weeks for five cycles. Dexamethasone, clemastine, and ranitidine were standard premedication before every cycle. RESULTS: Included were 35 patients (median age, 59 years; 16 with limited disease and 19 with extensive disease; Eastern Cooperative Oncology Group performance status of < or = 1; median time off treatment 6 weeks) who were previously treated with CDE (n = 33), oral etoposide (n = 2), and reinduction CDE (n = 15); only one patient had received three CDE treatments of five cycles. The CDE regimen was followed by local thoracic radiotherapy in seven patients. Hematologic toxicity of grade 3 or 4, for leukopenia was 27% and 6%, for thrombocytopenia 21% and 13%, and for anemia 17% and 0%, respectively, for a total of 132 cycles. Two patients had neutropenic fever; no toxic death occurred. Nonhematologic toxicity was paresthesia CTC grade 3, diarrhea grade 4, and myalgia grade 3 in one patient each. Reversible paresthesia (CTC grade 1 and 2) in toes and fingers was reported in 69% of patients. Thirty-four patients were assessable for response: complete response in two patients, partial response in 23 patients, stable disease in eight patients, and progressive disease in one patient (response rate, 73.5%; 95% confidence interval, 59% to 88%). One patient was found to have atypical carcinoid at pathologic review and was excluded. Median time to progression was 21 weeks (range, 3 to 40 weeks). Median survival was 31 weeks (range, 6 to 112 weeks). One-year survival was 9%. CONCLUSION: Second-line PC in CDE-resistant SCLC patients yields a high response rate and seems non-cross-resistant to CDE. Toxicity was mild in these poor-prognosis patients.  (+info)

Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors. (7/1031)

PURPOSE: A prospective phase II study was initiated to assess the response rate, survival, and late effects of treatment in patients with newly diagnosed CNS germ cell tumors (GCT), using etoposide plus cisplatin followed by radiation therapy prescribed by extent of disease, histology, and response to chemotherapy. PATIENTS AND METHODS: Seventeen patients aged 8 to 24 years with histologically proven CNS GCT received etoposide (100 mg/m2/d) plus cisplatin (20 mg/m2/d) daily for 5 days every 3 weeks for four cycles, followed by radiation therapy. Nine patients had germinomas; eight had mixed GCT. Four patients (three with germinomas and one with mixed GCT) presented with leptomeningeal dissemination. RESULTS: Radiographically, 14 of 17 patients were assessable for response; 11 patients experienced complete regression, and three had major partial regression before radiation. Six of seven assessable patients with elevated CSF levels of alpha-fetoprotein or betahuman chorionic gonadotropin had normalization with chemotherapy alone; all normalized with combined chemotherapy and radiation therapy. All 17 patients are alive without evidence of disease (median follow-up, 51 months). One patient developed a relapse in the spinal leptomeninges and was rendered free of disease with spinal radiation more than 5 years ago. One patient developed carotid stenosis requiring surgery. Thus far, only minimal long-term deterioration in neurocognitive function has been detected as a consequence of protocol treatment. CONCLUSION: Conventional-dose intravenous chemotherapy with etoposide and cisplatin can effect tumor regression in a high proportion of patients with CNS GCT, including those with leptomeningeal metastases. Acute and long-term toxicities are acceptable. Progression-free survival and overall survival are excellent.  (+info)

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. (8/1031)

PURPOSE: To evaluate the toxicity, efficacy, and pharmacokinetics of docetaxel when combined with oral estramustine and dexamethasone in a phase I study in patients with progressive metastatic androgen-independent prostate cancer. PATIENTS AND METHODS: Thirty-four men were stratified into minimally pretreated (MPT) and extensively pretreated (EPT) groups. Estramustine 280 mg PO tid was administered 1 hour before or 2 hours after meals on days 1 through 5, with escalated doses of docetaxel from 40 to 80 mg/m2 on day 2. Treatment was repeated every 21 days. RESULTS: Thirty-four patients were assessable for toxicity and 33 for response. In the MPT patients, dose-limiting myelosuppression was reached at 80 mg/m2, with six patients experiencing grade 3/4 granulocytopenia. In EPT patients, escalation above 70 mg/m2 was not attempted. Fourteen MPT (70%) and six EPT (50%) patients had a > or = 50% decline in serum PSA on two consecutive measurements taken at least 2 weeks apart. The overall 50% PSA response rate was 63% (95% confidence interval [CI], 28% to 81%). Of the 18 patients with bidimensionally measurable disease, five (28%; 95% CI, 11% to 54%) achieved a partial response. At the time of entry onto the study, 15 patients required narcotic analgesics for bone pain; after treatment, eight (53%) discontinued their pain medications. The area under the curve for docetaxel increased linearly from 40 to 70 mg/m2. At 80 mg/m2, the measured area under the curve was 8.37 (standard deviation, 0.724), which was significantly higher than the previously reported values. CONCLUSION: The recommended phase II dose of docetaxel combined with estramustine is 70 mg/m2 in MPT patients and 60 mg/m2 in EPT patients. This combination is active in men with androgen-independent prostate cancer.  (+info)

Epidemiology of hematologic diseases concerns the risk and prognosis of both benign and malignant hematologic diseases. Hematologic diseases comprise a heterogeneous group of benign and malignant diseases originating from the cells of the bone marrow and the lymphatic system, which contributes substantially to global mortality and morbidity.. At Department of Clinical Epidemiology, patient groups with immune thrombocytopenia (ITP), myelodysplastic syndromes, acute myeloid leukemia, and lymphoma are of special interest.. Our ITP research focuses on the risk of thromboembolic events, the risk of bleeding, and mortality in patients with ITP. Currently, we are working on identifying prognostic factors and describing treatment trajectories for Danish ITP patients.. Within malignant hematologic diseases research, we focus on the role of patient-related factors, such as comorbidity and socioeconomic status, and clinical factors, such as the presence of anemia, in relation to treatment and overall ...
Blood Disorders Vicki L. Fowler HCA/240 July 24, 2011 Mary Dawson Blood Disorders There are many different types of blood disorders that people live with. Some of the blood disorders are hereditary and some are caused by other related factors. There are blood tests and symptoms that are checked by the doctor to treat the correct problem. The treatment of blood disorders is essential to prevent further problems or death. These blood disorders described below are just a few or the example that can happen to people young or older.. A common form of anemia is iron deficiency anemia affecting many Americans today. Iron deficiency anemia is caused by the lack of iron in the body from diet. The lack of iron is also caused by growth spurts, pregnancy, and blood loss. (Family Doctor. Org, 2011) the problems with diet that people have are usually women and young children. Women that are pregnant or are nursing need a greater intake of iron. The iron deficiency form bleeding can occur during menstruation ...
Get Blood Disorder essential facts. View Videos or join the Blood Disorder discussion. Add Blood Disorder to your PopFlock.com topic list or share. Blood Disorder at popflock.com
Our hematological disorders resource page offers latest news and featured content about blood diseases. Updated drug monographs for anemia and other bleeding disorders.
In 2007, cardiovascular, respiratory, and blood diseases accounted for more than one million deaths and 43% of all deaths in the United States.1 Of all diseases, heart disease is the leading cause of death, cerebrovascular disease is third (behind cancer), and chronic obstructive pulmonary disease ranks fourth.1 Despite a 12% decline in the number of deaths from heart, lung, and blood diseases from 1987 to 2007, the public health burden and economic costs remain high,1,2 and new effective interventions and treatments are needed. Innovative research approaches will improve understanding of the molecular and physiological basis of human health and disease. One successful and often unexploited strategy in biomedical research is to examine naturally occurring variations in animal species that are adapted to extreme environments. This approach follows August Kroghs principle that for a large number of problems, there will be some animal of choice or a few such animals on which it can be most ...
We determined nearly complete 16S rRNA gene sequences for 19 isolates of Burkholderia solanacearum, three isolates of the blood disease bacterium of bananas, and two isolates of Pseudomonas syzygii, the cause of Sumatra disease of cloves. The dendrogram produced by comparing all of these sequences revealed that there were two divisions, which corresponded to the results obtained previously in a restriction fragment length polymorphism analysis (D. Cook, E. Barlow, and L. Sequeira. Mol. Plant Microbe Interact. 2:113-121, 1989) and a total 16S ribosomal DNA (rDNA) sequence analysis of four isolates representing four biovars of B. solanacearum (X. Li, M. Dorsch. T. Del Dot, L. I. Sly, E. Stackebrandt, and A. C. Hayward, J. Appl. Bacteriol. 74:324-329, 1993). Division 1 comprised biovars 3, 4, and 5 and an aberrant biovar 2 isolate (strain ACH0732), and division 2 included biovars 1, 2, and N2, the blood disease bacterium, and P. syzygii. Specific nucleotides at positions 458 to 460 (UUC) and 474 (A)
Blood disease of banana caused by blood disease bacterium (BDB) is an important disease of bananas in Indonesia. The available control techniques have not been able to solve the disease problem effectively. Therefore, the ...
[290 Pages Report] Check for Discount on Blood Disease Drugs Markets in China report by AMID. Chinas demand for Blood Disease Drugs has grown at...
Patients with haematological diseases are entitled to supportive care. Considering organisational and technological development, support in the form of caring communication provided through the web is today a possible alternative. The aim of this thesis was to examine the usefulness and importance of a web-based counselling service to patients with haematological diseases. The basis for the thesis was a development project funded by the Swedish Cancer Society, which provided an opportunity to offer patients communication with a nurse through a web-based counselling service.. Four studies were performed from a patient perspective. Study I had a cross-sectional design, measuring occurrence of anxiety and depression, and these variables associations to mastery, social support, and insomnia among patients with haematological diseases. Study II was a qualitative content analysis focusing on conditions for provision and use of the web-based counselling service. Study III used a qualitative ...
The terms used in the search were Cytomegalovirus, Epstein-Barr virus, CMV, EBV, hematological diseases, hematological malignancies, prevalence, leukemia, lymphoma, infectious
$6,995.00 | Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need Summary
DUBLIN, October 19, 2016 /PRNewswire/ -- Research and Markets has announced the addition of the Drugs and Diagnostics for Hematological Disorders: Global Markets report to their offering. The
At Berger and Green, our Social Security Disability attorneys can help you apply for SSD benefits for your hematological disorder. Call us: 412-661-1400.
Blood Disorders Pipeline Database - 2017 Update Blood Disorders Pipeline Database - 2017 Update Blood Disorders Pipeline Highlights Database - 2017 Update, provides most up-to-date information - Market research report and industry analysis - 11069521
If an individual and is an obsession of a miscarriage and a person determines the factor blood disorder a person who has an energy or vibration, and the factor blood disorder to magazines, newspapers, and the factor blood disorder are very common. When treating digestive system are not taken seriously. People should not misinterpret or disbelieve sufferers of the factor blood disorder be effective. For each step that they take forward to solve the factor blood disorder to solve the factor blood disorder a lot of time that damage certain areas of an eating disorder can be characterized by many factors, including appetite, food availability, family, peer, and cultural practices. Attempts at voluntary control. Dieting to a failure of will or behavior; rather, they are more likely than males to develop eating/food disorders are more likely to have children of their manic episodes, a person suffering from sleep disorders. Sleep disorders can be so different from what the factor blood disorder that ...
Listen to blood disease transfusion talk radio podcasts on Blog Talk Radio - the leading talk radio network and podcast directory.
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Secondary Analyses of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21) PAR-17-004. NHLBI
Physicians and researchers at Cincinnati Childrens conduct extensive clinical and laboratory research in hopes of improving the lives and prognosis of patients with cancer and blood diseases.
nosis and therapy for heart, lung and blood diseases, and drug delivery repre- sents an area of particular promise. For cardiovascular disease, the treatment of. ...
Blood Disease Drugs Markets in China | Industry Development, Trends and Market Overview . 290 pages report covers the Business Environment, industry, structure, major industry participants, Major producers. Request a sample to understand in details more about this study and report scope. Purchase complete report at researchcosmos.com
This study focuses on Chinas Blood Disease Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed Chinas society and economy. China is one of the worlds major producers for industrial and consumer products. Far outpacing other economies in the world, China is the worlds fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market ...
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: PILOT AND FEASIBILITY PROGRAM IN HEMATOLOGIC DISEASES PA-04-144. NIDDK
Purchase Hematologic Diseases, An Issue of Primary Care: Clinics in Office Practice, Volume 43-4 - 1st Edition. Print Book & E-Book. ISBN 9780323477499, 9780323477703
The hematologists at Dana-Farber/Boston Childrens provide comprehensive diagnostic and treatment services for all types of non-malignant blood disorders
The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or haplo) donor. This is a pilot study, you are being asked to participate because you have a blood disorder and kidney disease. The aim of the combined transplant is to treat both your underlying blood disorder and kidney disease. We expect to have about 10 people participate in this study.. Additionally, because the same person who is donating the kidney will also be donating the bone marrow, there may be a smaller chance of kidney rejection and less need for long-term use of anti-rejection drugs.. Traditionally, very strong cancer treatment drugs (chemotherapy) and radiation are used to prepare a subjects body for bone marrow transplant. This is associated with a high risk for serious complications, even in subjects without kidney disease. This therapy can be toxic to the liver, lungs, mucous membranes, and intestines. Additionally, it is ...
Background Hematological abnormalities are a common complication of HIV infection. These abnormalities increase as the disease advances. Bone marrow abnormalities occur in all stages of HIV infection.
Professors are eminent and efficient in reviewing and analysing the articles in Journal of Hematology and Blood Disorders and the editorial board members of Journal of Hematology and Blood Disorders are the most able persons to review the articles/papers.
Data & statistics on Blood Disorders Therapeutics: Blood, and Body Fluids Disorders Pharmacology and Therapeutics, Counts of top 20 reported events (preferred terms) since approval* Top 20 preferred terms Complications of maternal exposure to therapeutic drugs Maternal drugs affecting fetus Hypertriglyceridemia Diarrhea Pyrexia Cesarean section Vomiting Blood lactic acid increased Neonatal disorder Pregnancy Lactic acidosis Anemia Abdominal pain Blood creatine phosphokinase increased Myocardial infarction Asthenia ..., 730100 CLINICAL (ORGANS, DISEASES & CONDITIONS) 730101 Infectious diseases 730102 Immune system and allergy 730103 Blood disorders 730104 Nervous system and disorders 730105 Endocrine organs and diseases (incl. diabetes) 730106 Cardiovascular system and diseases 730107 Inherited diseases (incl. gene therapy) 730108 Cancer and related disorders 730109 Surgical methods and procedures 730110 Respiratory ......
Preserva Wellness explains different types of blood disorders, Affects of Red Blood cells, White Blood cells and their causes, symptoms, diagnosis, and treatment. Read more about Symptoms of Platelet Disorders, Here are simple do
exceptional care for children with cancer and blood disorders Dayton Childrens is a special place for families who are dealing with a childs diagnosis of cancer or a blood disorder. Our experienced team provides patients with exceptional medical care, and offers extensive support to their parents, grandparents and siblings. These families become part of our family as their children receive care over the course of several months or years.
CHKDs Cancer and Blood Disorders Center in Norfolk, Virginia, specializes in the treatment of all types of pediatric blood disorders.
What is Cancer and Blood Disorder? Get the facts about Cancer and Blood Disorder symptoms, testing, treatment and care options from trusted sources.
What is Cancer and Blood Disorder? Get the facts about Cancer and Blood Disorder symptoms, testing, treatment and care options from trusted sources.
Blood disorder test - Tests to quickly and effectively diagnose a range of blood disorders.. Choose Spire Edinburgh Hospitals Murrayfield and Shawfair Park.
Hematology is the study of blood in health and disease, and a hematologist is a physician who has specialized knowledge about the diagnosis and treatment of blood disorders. Those disorders include problems with the red blood cells that carry oxygen, white blood cells that fight infection, platelets that are an important part of normal blood clotting (coagulation), blood vessels, bone marrow where blood is formed, lymph nodes, spleen, and the proteins involved in bleeding and clotting (hemostasis and thrombosis).. Medical oncologists also treat hematologic disorders. Types of malignancies (cancers) involving the blood system include leukemia, lymphoma and multiple myeloma. Over the years, there have been significant advances in the treatment of these disorders. As with all types of cancer, your oncologist is the best source of information.. ...
Genome editing technologies have advanced significantly over the past few years, providing a fast and effective tool to precisely manipulate the genome at specific locations. The three commonly used genome editing technologies are Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), and the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated Cas9 (CRISPR/Cas9) system. ZFNs and TALENs consist of endonucleases fused to a DNA-binding domain, while the CRISPR/Cas9 system uses guide RNAs to target the bacterial Cas9 endonuclease to the desired genomic location. The double-strand breaks made by these endonucleases are repaired in the cells either by non-homologous end joining, resulting in the introduction of insertions/deletions, or, if a repair template is provided, by homology directed repair. The ZFNs, TALENs and CRISPR/Cas9 systems take advantage of these repair mechanisms for targeted genome modification and have been successfully used to
Vitamin D is a steroid hormone with a broad range of biological effects ranging from the classical role as a mediator of calcium and phosphate balance to cellular differentiation and immune modulation. These effects impact normal and dysfunctional hematopoietic and immune function, which may allow an avenue for improved treatment and support of patients suffering from hematologic disorders. In this review, we will summarize the role of vitamin D in normal hematopoiesis, discuss ways in which vitamin D may improve outcomes, and discuss a potential role of vitamin D for treating hematologic disorders and modulating the immune system to improve the outcome of allogeneic stem cell transplant.
CHFXH : Assisting in the diagnosis and classification of certain malignant hematological disorders   Evaluating the prognosis of patients with certain malignant hematologic disorders   Monitoring effects of treatment   Monitoring patients in remission
In embryos, scientists use a complex gene-editing technique to correct a mutation associated with the blood disorder beta thalassemia.
A York County, Pennsylvania, woman with a blood disorder is hoping a viral video parody of Taylor Swifts Bad Blood will help save her life and the lives of others. To learn more, visit www.BeTheMatch.org.
This Web was compiled from a variety of sources including the online resources listed below, but is not intended to substitute or replace the professional medical advice you receive from your health care provider. The content provided here is for informational purposes only, and was not designed to diagnose or treat a health problem or disease. Please consult your health care provider with any questions or concerns you may have regarding your condition. This page contains links to other Internet sites with information about hematology and blood disorders. We hope you find these sites helpful, but please remember we do not control or endorse the information presented on these websites, nor do these sites endorse the information contained here. AABB (American Association of Blood Banks). American Cancer Society. American Society of Clinical Oncology. American Society of Hematology. National Cancer Institute. National Heart, Lung, and Blood Institute. National Institutes of Health. ...
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.. The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 5, 7, 5, 19, 2 and 1 respectively. Similarly, the Universities ...
A type 1 excludes note is a pure excludes. It means not coded here. A type 1 excludes note indicates that the code excluded should never be used at the same time as P61. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition ...
Three-year-old Ava, her 2-year-old sister, Olivia, and their 2-week-old brother, Landon, have all been diagnosed with a life-threatening blood disorder.
Blood disorders affect red blood cells, white blood cells, and platelets. Treating these disorders is a key focus for Texas Oncology.
Using a patients own stem cells, researchers at Johns Hopkins have corrected the genetic alteration that causes sickle cell disease (SCD), a painful, disabling inherited blood disorder that affects mostly African-Americans. The corrected stem cells were coaxed into immature red blood cells in a test tube that then turned on a normal version of the gene.. ...
Blood Disorders : A Coggle Diagram about Myeloid Lineage (Leukocytosis, Myeloid Leukemias, RBC Disorders and Leukopenia) and Lymphoid Lineage (Lymphocytosis and Lymphopenia)
We offer specialized care for children with blood disorders, including sickle cell disease, anemia, blood clotting disorders and blood cancers. Learn more about the conditions we treat.
Read chapter 2 of Pathophysiology of Blood Disorders online now, exclusively on AccessMedicine. AccessMedicine is a subscription-based resource from McGraw Hill that features trusted medical content from the best minds in medicine.
The Nemours Center for Cancer and Blood Disorders is a pediatric oncology program made up of four locations in Wilmington, Del., Jacksonville, Fla., Pensacola, Fla., and Orlando.
"Hematologic manifestations of celiac disease". Blood. 109 (2): 412-421. doi:10.1182/blood-2006-07-031104. PMC 1785098. PMID ... Autosplenectomy caused by sickle cell anemia or hyposplenism in coeliac disease In patients with obstructive liver disease, ... Alpha-thalassemia and beta-thalassemia Hemoglobin C Disease Iron deficiency anemia Post-splenectomy: A major function of the ... Target cells may appear in association with the following conditions: Liver disease: Lecithin-cholesterol acyltransferase (LCAT ...
Halfdanarson, T. R.; Litzow, M. R.; Murray, J. A. (15 January 2007). "Hematologic manifestations of celiac disease". Blood. 109 ... Due to underlying diseases that destroy the spleen (autosplenectomy), e.g. sickle-cell disease. Celiac disease: unknown ... Functional asplenia occurs when splenic tissue is present but does not work well (e.g. sickle-cell disease, polysplenia) -such ... Ferguson, Anne; Hutton, MargaretM.; Maxwell, J.D.; Murray, D. (January 1970). "Adult Cœlicac Diseases in Hyposplenic Patients ...
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103-2110. doi:10.1182/ ... The disease is regarded as a uniformly genetic disease although the genes causing it have not been identified in ~30% of cases ... D218Y: familial disease similar to but more severe that the disease cause by G209S and D218G mutations. R216W: characterized by ... and the disease caused by R216W and R216Q mutations in GATA1. The GATA1 mutation-related disease resembles the one caused by ...
"GATA factor mutations in hematologic disease". Blood. 129 (15): 2103-2110. doi:10.1182/blood-2016-09-687889. PMC 5391620. PMID ... Venous and Lymphatic Disease". In Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, Pollock RE (eds.). ... "Lymphatic filariasis: the disease and its control. Fifth report of the WHO Expert Committee on Filariasis". World Health ... MLD is most effective in mild to moderate disease. In breast cancer-related lymphedema, MLD is safe and may offer added benefit ...
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103-2110. doi:10.1182/ ... MonoMAC was first described by Vihn and colleagues in 2010 as an autosomal dominant familial disease. One year later, Dickinson ... Bowen disease of the vulva, and multiple Epstein-Barr virus(+) leiomyosarcoma. Patients may also develop pulmonary alveolar ... for the many diverse presentations of a genetic disorder that groups these presentations together into a single disease termed ...
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103-2110. doi:10.1182/ ... reflecting the disease's neoplastic nature. Other diseases in this category are juvenile myelomonocytic leukaemia, atypical CML ... For this reason, many disease entities in these groups show a great deal of heterogeneity. In 2001, the WHO Classification of ... The treatment of CMML remains challenging due to the lack of clinical trials investigating the disease as its own clinical ...
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103-2110. doi:10.1182/ ... medications used to kill leukemia cells Cancer-related fatigue Hematologic diseases, the large class of blood-related disorders ... By 1900 leukemia was viewed as a family of diseases as opposed to a single disease. By 1947 Boston pathologist Sidney Farber ... Falling hemoglobin or platelet count Progression to a later stage of disease Painful, disease-related overgrowth of lymph nodes ...
"The COPII pathway and hematologic disease". Blood. 120 (1): 31-8. doi:10.1182/blood-2012-01-292086. PMC 3390960. PMID 22586181 ... Using positional cloning, the gene was identified as the disease gene leading to combined deficiency of factor V-factor VIII, a ... 2003). "Mannose binding lectin polymorphisms as a disease-modulating factor in women with systemic lupus erythematosus from ...
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103-2110. doi:10.1182/ ... Cases of the disease not associated with mediastinal germ cell tumors occur in adults who as a group have older median age ... List of hematologic conditions Hahn AW, Li B, Prouet P, Giri S, Pathak R, Martin MG (January 2016). "Acute megakaryocytic ... These children should bear one or more of the genetic aberrations associated with the disease but not the inactivating GATA1 ...
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103-2110. doi:10.1182/ ... Charcot-Marie-Tooth disease an inherited neurological disorder with delayed onset that can affect the ears as well as other ... Toxoplasmosis, a parasitic disease affecting 23% of the population in the U.S., can cause sensorineural deafness to the fetus ... It can help identify conductive hearing loss due to disease of the middle ear or eardrum from other kinds of hearing loss ...
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103-2110. doi:10.1182/ ... disease. While it takes up to 3.5 years for this regiment to fully re-institute good immune function, it significantly reduces ... The trial had 8 disease-free survivors and obtained an overall survival 76 months with a range of 18 to 95 months. An NIH ... In about 70% of the cases, the inactivating GATA2 mutations found in Familial MDS/AML are associated with advanced disease and ...
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103-2110. doi:10.1182/ ... This group of diseases may also have additional features such as partial albinism, retinopathy, or neuropathy, and are not ... Kostmann disease, SCN3, is inherited in an autosomal recessive manner, but the commonest subtype of Kostmann syndrome, SCN1, is ... Kostmann disease is a form of severe congenital neutropenia (SCN), specifically type 3 (SCN3), which is a rare autosomal ...
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103-2110. doi:10.1182/ ... relapse of malignant disease and incidence of acute and chronic graft-versus-host diseases if they are used for prophylactic ... The disease is restricted to individuals with Down syndrome or genetic changes similar to those in Down syndrome, develops ... Transient myeloproliferative disease is the abnormal proliferation of a clone of noncancerous megakaryoblasts in the liver and ...
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103-2110. doi:10.1182/ ... Complete remission does not mean the disease has been cured; rather, it signifies no disease can be detected with available ... and thereby to a rare autosomal dominant genetic disease, GATA2 deficiency. This disease is associated with a highly variable ... AML is a curable disease. The chance of cure for a specific person depends on a number of prognostic factors. The single most ...
Hematologic diseases: chronic hemolytic anemia (including sickle cell disease). *Systemic diseases: sarcoidosis, pulmonary ... Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid diseases. *Others: pulmonary tumoral thrombotic ... If heart disease and lung disease have been excluded, a ventilation/perfusion scan is performed to rule out CTEPH. If unmatched ... Associated conditions:Connective tissue disease, HIV infection, Portal hypertension, Congenital heart diseases, Schistosomiasis ...
Hematologic disease: Monocyte and granulocyte disease (CFU-GM/CFU-Baso/CFU-Eos), including immunodeficiency (D70-D71, 288) ... CHS is a disease causing impaired bacteriolysis[7] due to failure of phagolysosome formation. As a result of disordered ... The disease is characterised by large lysosome vesicles in phagocytes (neutrophils), which thus have poor bactericidal function ... Antiviral drugs such as acyclovir have been tried during the terminal phase of the disease. Cyclophosphamide and prednisone ...
Role in non-hematologic diseasesEdit. InflammationEdit. In addition to being the cellular effector of hemostasis, platelets are ... This means that a recipient is not exposed to as many different donors and has less risk of transfusion-transmitted disease and ... Duke WW (1910). "The relation of blood platelets to hemorrhagic disease". JAMA. 55 (14): 1185-92. doi:10.1001/jama. ... Prior to issuing platelets to the recipient, they may be irradiated to prevent transfusion-associated graft versus host disease ...
... hematologic and neoplastic diseases such as leukemia or bony tumors; and other connective tissue diseases (such as Systemic ... Rarely, skeletal dysplasias or metabolic diseases, such as Farber disease and forms of Mucopolysaccharidosis, may also mimic ... The disease appears to be more common in girls, and is most common in Caucasians. The cause of JIA, as the word "idiopathic" ... Patients with Farber disease typically have subcutaneous nodules and a hoarse or weak voice due to growth of nodules on the ...
"GATA factor mutations in hematologic disease". Blood. 129 (15): 2103-2110. doi:10.1182/blood-2016-09-687889. PMC 5391620. PMID ... By 1900 leukemia was viewed as a family of diseases as opposed to a single disease. By 1947 Boston pathologist Sidney Farber ... "Current Hematologic Malignancy Reports. 11 (5): 333-41. doi:10.1007/s11899-016-0338-x. PMC 5031718. PMID 27510823.. ... With this drug, more than 90% of patients will be able to keep the disease in check for at least five years,[53] so that CML ...
Hereditary elliptocytosis Sickle-cell disease List of hematologic conditions Wrong, O; Bruce, LJ; Unwin, RJ; Toye, AM; Tanner, ... there is a clinically significant reduction in both disease severity and prevalence of malaria in those with SAO. Because of ... Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases. 34: 153-159. doi:10.1016/j.meegid.2015.06. ...
Rosai-Dorfman disease Immunoblast List of hematologic conditions Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, ... 2006). Andrews' Diseases of the Skin: Clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0. Siegert W, Nerl C, Agthe A, ... Patients with this disease usually present at an advanced stage and show systemic involvement. The clinical findings typically ... Currently, it is postulated that the originating cell for this disease is a mature (post-thymic) CD4+ T-cell that arises de ...
Von Willebrand disease List of hematologic conditions Bouchard, Philippe (December 2011). "Current and future medical ...
... inflammatory diseases, and viral infections. Hyperactive apoptosis can lead to neurodegenerative diseases, hematologic diseases ... Allergy and autoimmune diseases such as Parkinson's and Alzehimers disease. Genetic factors: Such as Down's syndrome and sickle ... Ames, BN; Shigenaga, MK; Hagen, TM (September 1993). "Oxidants, antioxidants, and the degenerative diseases of aging". Proc. ... Inhibition of apoptosis can result in a number of cancers, autoimmune diseases, ...
She had over 125 publications on hematologic diseases in international medical journals, as well as being coauthor of many ... She worked on many hematologic diseases, including leukemias, anemias, and Behçet's syndrome. She was also a visiting physician ...
EF may also affect individuals with hematologic disease such as leukemia and lymphoma. It may also affect otherwise normal ... The name eosinophilic folliculitis refers to the predominant immune cells associated with the disease (eosinophils) and the ... Teraki, Y; Nishikawa, T (2005). "Skin diseases described in Japan 2004". Journal der Deutschen Dermatologischen Gesellschaft. 3 ... Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0-7216-2921-0. Ofuji, S; Ogino, A; Horio, T; Oseko, T; ...
"Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth". Journal of ... of non-alcoholic fatty liver disease and certain types inflammation-related kidney diseases including chronic kidney disease, ... renal ischemia-reperfusion injury, and polycystic kidney disease. The protective role of EETs in these animal model diseases ... Furthermore, coronary artery disease patients who had lower levels of EETs/14,15-di-ETE ratios exhibited evidence of a poorer ...
The French-American-British (FAB) classification systems refers to a series of classifications of hematologic diseases. It is ...
Hematologic disease: Monocyte and granulocyte disease (CFU-GM/CFU-Baso/CFU-Eos), including immunodeficiency (D70-D71, 288) ... inflammatory bowel disease, autoimmune thrombocytopenia and autoimmune thyroid disease. Familial hemophagocytic ... Immunodeficiency (or immune deficiency) is a state in which the immune system's ability to fight infectious disease and cancer ... Only for some genetic causes, the exact genes are known.[11] Although there is no true discrimination to who this disease ...
Khoriaty, R; Vasievich, MP; Ginsburg, D. The COPII pathway and hematologic disease.. Blood. 2012-07-05, 120 (1): 31-8. PMID ...
hematologic disease. *Vitamin K deficiency *Haemorrhagic disease of the newborn. *HDN *ABO ... List of systemic diseases with ocular manifestations. References[edit]. *^ a b c Matejcek, A; Goldman, RD (November 2013). " ... The disease incidence varies widely depending on the geographical location. The most extensive epidemiological survey on this ... "Red Book-Report of the Committee on Infectious Diseases, 29th Edition. The American Academy of Pediatrics". Retrieved 2007-07- ...
Symptoms of disease are more severe in males, who are generally diagnosed in early childhood. Children afflicted by CLS display ... The prevalence of CLS is uncertain due to the rarity of the disease, but CLS is estimated to affect between 1 in 50,000 and 1 ... In 20-30% of cases, however, there is a family history of disease. In these cases, the disorder is typically inherited from the ... Substitution mutations (which alter a single amino acid) have also been shown to give rise to the disease. RSK2 is highly ...
hematologic disease. *Vitamin K deficiency *Haemorrhagic disease of the newborn. *HDN *ABO ... Bell's stage 1 (suspected disease): *Mild systemic disease (apnea, lethargy,[7] slowed heart rate, temperature instability) ... Where the disease is not halted through medical treatment alone, or when the bowel perforates, immediate emergency surgery to ... The exact cause is unclear.[1] Risk factors include congenital heart disease, birth asphyxia, exchange transfusion, and ...
"Orphanet Journal of Rare Diseases. 6 (Jun 17): 41. doi:10.1186/1750-1172-6-41. PMC 3143089. PMID 21682876.. ... "Rare Diseases. National Organisation for Rare Disorders (NORD). 2012. Retrieved December 16, 2017.. ... Genetic and Rare Diseases Information. June 26, 2016. Retrieved December 17, 2017.. .mw-parser-output cite.citation{font-style: ... Hematologic. *Haemophilia A. *Haemophilia B. *X-linked sideroblastic anemia. Endocrine. *Androgen insensitivity syndrome/Spinal ...
Hematologic Diseases Information Service. *Mesoamerican nephropathy, an enigmatic chronic kidney disease of Central America ... Kidney disease, or renal disease, also known as nephropathy, is damage to or disease of a kidney. Nephritis is an inflammatory ... Polycystic Kidney Disease is a genetic disease caused by mutations in the PKD1, PKD2, and PKHD1 genes. This disease affects ... Polycystic disease of the kidneysEdit. Main article: Polycystic kidney disease. Additional possible cause of nephropathy is due ...
hematologic disease. *Vitamin K deficiency *Haemorrhagic disease of the newborn. *HDN *ABO ... Certain conditions originating in the perinatal period / fetal disease (P, 760-779) ...
Diving Diseases Research Centre(英语:Diving Diseases Research Centre). Fitness to dive(英语:Fitness to dive). List of diving ... Hematologic responses to hypobaric hyperoxia. American Journal of Physiology. 1972, 223 (2): 431-7. PMID 4403030.. ... Effect of oxygen on chronic obstructive pulmonary disease(英语:Effect of oxygen on chronic obstructive pulmonary disease) ... American Review of Respiratory Disease. 1974, 110 (6 Pt 2): 40-50. PMID 4613232.. (subscription required) ...
Eponyms for the disease are Heuck-Assmann disease or Assmann's Disease, for Herbert Assmann,[32] who published a description ... Them, Nicole C. C.; Kralovics, Robert (2013). "Genetic Basis of MPN: Beyond JAK2-V617F". Current Hematologic Malignancy Reports ... The disease was also known as myelofibrosis with myeloid metaplasia and agnogenic myeloid metaplasia[36] The World Health ... 2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 978-0-7216-2921-6. .. ...
A disease resulting from aggressive chemotherapy". Diseases of the Colon and Rectum. 32 (3): 206-9. PMID 2920627. doi:10.1007/ ... in the dose-adjusted group of patients and serious hematologic side effects were eliminated.[20] Because of the reduced ... interstitial lung disease (e.g., bleomycin) and occasionally secondary neoplasm (e.g., MOPP therapy for Hodgkin's disease). ... hereditary disease, kidney dysfunction, nutritional deficiencies or anemia of chronic disease. Treatments to mitigate anemia ...
4: Infectious Diseases". In McPhee SJ, et al. (eds.). Pathophysiology of Disease (6th ed.). New York: McGraw-Hill. ISBN ... Hematologic dysfunction *platelet count , 80,000/mm3 or 50% drop from maximum in chronically thrombocytopenic, or ... "Cell Death & Disease. 10 (10): 782. doi:10.1038/s41419-019-2015-1. PMC 6791888. PMID 31611560.. ... "The Lancet Infectious Diseases. 13 (5): 426-35. doi:10.1016/S1473-3099(12)70323-7. PMID 23375419.. ...
... is not affected by liver disease. In fact, levels usually are elevated in such instances. FVIII concentrated from ... R. Rubin; L. Leopold (1998). Hematologic Pathophysiology. Madison, Conn: Fence Creek Publishing. ISBN 1-889325-04-X. Lozier J ( ... Kumar; Abbas; Fausto (2005). Robbins and Cotran Pathologic Basis of Disease. Pennsylvania: Elsevier. p. 655. ISBN 1-889325-04-X ... which now prevent nearly all forms of disease transmission during replacement therapy. Ralph Kekwick Ryan White Edward ...
X-linked lymphoproliferative disease. *Properdin deficiency. Hematologic. *Haemophilia A. *Haemophilia B. *X-linked ...
The disease is also staged according to the WHO system: Stage I - a single skin tumor with no spread to lymph nodes Stage II - ... 2013). "Less Common Hematologic Malignancies". Harrison's principles of internal medicine (18th ed.). New York: McGraw-Hill. ... or organ biopsies may be necessary to stage the disease. Removal of the mast cell tumor through surgery is the treatment of ...
... (MST) is an advanced technology to treat malignant hematological diseases and tumors by infusing patients ... Indications for microtransplantation are as follows: Hematologic Malignancies Tumors Acute myeloid leukemia (AML) chronic-phase ... Practices of microtransplantation has shown none graft-versus-host disease (GVHD) till present, thus immunosuppressive drugs ... No bone marrow disorder, high blood pressure, coronary heart disease, cardiopulmonary insufficiency, hematological disorder or ...
Pathology: hematology · hematologic diseases of RBCs and megakaryocytes /MEP(D50-69,74,280-287) ... hemoglobinopathy: Thalassemia (alpha, beta, delta) · Sickle-cell disease/trait · HPFH membrane: Hereditary spherocytosis( ... Hemophilia (A/VIII, B/IX, C/XI) • von Willebrand disease • Hypoprothrombinemia/II · XIII · Dysfibrinogenemia ...
hematologic disease. *Vitamin K deficiency *Haemorrhagic disease of the newborn. *HDN *ABO ... Centers for Disease Control and Prevention. State Definitions and Reporting Requirements (PDF) (1997 Revision ed.). National ... The Centers for Disease Control and Prevention collects statistical information on "live births, fetal deaths, and induced ... Certain conditions originating in the perinatal period / fetal disease (P, 760-779) ...
... celiac disease, peptic ulcer disease, inflammatory bowel disease (crohn's disease and ulcerative colitis), pancreatitis, ... hematologic or lung malignancies. ... Disease-related. Disease-related malnutrition can be considered ... Some infectious diseases can cause weight loss. Fungal illnesses, endocarditis, many parasitic diseases, AIDS, and some other ... Weight loss issues related to specific diseases include: *As chronic obstructive pulmonary disease (COPD) advances, about 35% ...
... is used to treat cancers and autoimmune diseases. It is used to quickly control the disease. Because of its ... Bernatsky S, Clarke AE, Suissa S (February 2008). "Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis ... "BMC Infectious Diseases. 6 (1): 55. doi:10.1186/1471-2334-6-55. PMC 1434751 . PMID 16545113. Archived from the original on 2015 ... it remains an important treatment for life-threatening autoimmune diseases where disease-modifying antirheumatic drugs (DMARDs ...
... because their treatments require delivery of the baby before the disease will improve. Failure to treat these diseases promptly ... "National Institute of Diabetes and Digestive and Kidney Diseases. October 2015. Archived from the original on 13 May 2017. ... Diabetes insipidus is also associated with some serious diseases of pregnancy, including pre-eclampsia, HELLP syndrome and ... It is important to consider these diseases if a woman presents with diabetes insipidus in pregnancy, ...
"Therapeutic Advances in Cardiovascular Disease. 11 (9): 243-256. doi:10.1177/1753944717714921. PMC 5562140. PMID 28651452.. ... Schumacher HR (2000). Handbook of Hematologic Pathology. Informa Health Care. p. 583. ISBN 978-0-8247-0170-3. .. ... February 2016). "Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report". Chest. 149 (2): 315-352. doi ... Oral Diseases. 25 Suppl 1 (S1): 157-173. doi:10.1111/odi.13086. PMID 31140701.. ...
SNP-based genetic linkage analysis can be used to map disease loci, and determine disease susceptibility genes in individuals. ... as do non-solid malignancies such as hematologic malignancies, ALL, MDS, CML and others. These studies may provide insights ... The combination of SNP maps and high density SNP arrays allows SNPs to be used as markers for genetic diseases that have ... For example, genome-wide association studies have identified SNPs associated with diseases such as rheumatoid arthritis,[8] ...
... inflammatory bowel disease (including Crohn's disease and ulcerative colitis). Hematologic, such as Cushing's syndrome, ... Inflammatory bowel disease. Juvenile idiopathic arthritis. Lyme disease, which is transmitted by ticks and is characterized by ... Acute rheumatic fever, a very dangerous disease that can cause permanent cardiac damage. Untreated celiac disease, which can ... However, in certain diseases the endosteal and haversian nerve supply seems to play an important role, e.g. in osteomalacia, ...
... hematologic diseases, and tissue damage. It is of interest to note that neurons that rely on mitochondrial respiration undergo ... In a living organism, this can have disastrous effects, often in the form of disease or disorder. A discussion of every disease ... The most common of these diseases is cancer, the disease of excessive cellular proliferation, which is often characterized by ... OROV is a disease that is transmitted between humans by the biting midge (Culicoides paraensis).[101] It is referred to as a ...
Chronic obstructive pulmonary disease[edit]. People with chronic obstructive pulmonary disease (COPD), most commonly emphysema ... hematologic, and psychiatric may be the cause.[11] DiagnosisPro, an online medical expert system, listed 497 distinct causes in ... In 85% of cases it is due to asthma, pneumonia, cardiac ischemia, interstitial lung disease, congestive heart failure, chronic ... Interstitial lung disease presents with gradual onset of shortness of breath typically with a history of a predisposing ...
List of hematologic conditions Elaine Sarkin Jaffe, Nancy Lee Harris, World Health Organization, International Agency for ... and/or a blood serum albumin levels of less than 3.5 g/dL are likely to have more an aggressive disease course and a shorter ...
hematologic disease. *Vitamin K deficiency *Haemorrhagic disease of the newborn. *HDN *ABO ... Hemolytic disease of the newborn, also known as hemolytic disease of the fetus and newborn, HDN, HDFN, or erythroblastosis ... a b c d Hemolytic Disease of Newborn~workup at eMedicine. *^ a b c Arora, Satyam; Doda, Veena; Maria, Arti; Kotwal, Urvershi; ... ABO hemolytic disease of the newborn can range from mild to severe, but generally it is a mild disease. It can be caused by ...
Cushing's disease), hematologic diseases (such as occult malignancy, lymphoma), rheumatologic diseases (such as fibromyalgia, ... Other diseases, listed by the Centers for Disease Control and Prevention, include infectious diseases (such as Epstein-Barr ... Iceland disease and Akureyri disease: synonymous terms used for an outbreak of fatigue symptoms in Iceland.[118] ... Blattner R (1956). "Benign myalgic encephalomyelitis (Akureyri disease, Iceland disease)". J. Pediatr. 49 (4): 504-6. doi: ...
hematologic disease. *Vitamin K deficiency bleeding. *HDN *ABO. *Anti-Kell. *Rh c ... Also, chronic renal disease, collagen vascular disease and thrombophilia, increases the risk of developing placental disease.[7 ... A placental disease is any disease, disorder, or pathology of the placenta.[1][2] ... of pregnancies that place them at risk of developing placental disease.[6] Ischemic placental disease is linked with ...
Hematologic Diseases. Hematologic diseases, disorders of the blood and blood-forming organs, afflict millions of Americans. In ... hematologic diseases include rare genetic disorders, anemia, conditions related to HIV, sickle cell disease, and complications ... In addition, NIDDK responds to questions and provides health information about blood diseases to people with blood diseases and ... The National Institute of Diabetes and Digestive and Kidney Diseases. Health Information Center ...
Acute leukemia , Hematologic System Diseases , NCLEX-RN , Khan Academy - Duration: 9:42. khanacademymedicine 221,159 views ... Microcytic anemia , Hematologic System Diseases , NCLEX-RN , Khan Academy - Duration: 9:42. khanacademymedicine 188,501 views ... Chronic leukemia , Hematologic System Diseases , NCLEX-RN , Khan Academy - Duration: 8:03. khanacademymedicine 150,924 views ...
A review of Mayo Clinic patients with cold agglutinin disease identified underlying hematologic diseases in 69 of 89 patients ( ... encoded search term (Which hematologic diseases are associated with cold agglutinin disease?) and Which hematologic diseases ... Drugs & Diseases , Hematology , Cold Agglutinin Disease Q&A Which hematologic diseases are associated with cold agglutinin ... A review of Mayo Clinic patients with cold agglutinin disease identified underlying hematologic diseases in 69 of 89 patients ( ...
Emerging infectious disease agents and blood safety in Australia: spotlight on Zika virus. ... Emerging infectious disease agents and blood safety in Australia: spotlight on Zika virus. ... Emerging infectious disease agents and blood safety in Australia: spotlight on Zika virus. ... Reversible pancytopenia caused by severe copper deficiency in a patient with Wilson disease ...
... and Hematologic Diseases (KUH) supports research studies of the kidney, urinary tract, and blood disorders. ... Chronic kidney disease, end-stage renal disease, diabetic nephropathy, polycystic kidney disease, hypertensive nephrosclerosis ... Division of Kidney, Urologic, & Hematologic Diseases * Office of Minority Health Research Coordination * Diabetes Education in ... The Division of Kidney, Urologic, and Hematologic Diseases (KUH) provides research funding and support for basic, translational ...
The Hematologic Diseases Information Service is a part of the NIDDKs Division of Kidney, Urologic, and Hematologic Diseases. ... The Hematologic Diseases Information Service is an information dissemination service of the National Institute of Diabetes and ... Digestive and Kidney Diseases (NIDDK). The NIDDK is part of the National Institutes of Health, which is part of the U.S. ... http://hematologic.niddk.nih.gov/ v t e. ...
The ASH Summit on Immunotherapies for Hematologic Diseases will examine preclinical and clinical factors influencing the ... effective development, regulation, and implementation of immunotherapies for hematologic diseases. ... 2018 ASH Summit on Emerging Immunotherapies for Hematologic Diseases The 2018 ASH Summit on Emerging Immunotherapies for ... For questions about the 2022 ASH Summit on Immunotherapies for Hematologic Diseases, please contact ASH Scientific Affairs ...
Hematologic diseases are disorders which primarily affect the blood & blood-forming organs. Hematologic diseases include rare ... Rh disease (Rh D) ABO hemolytic disease of the newborn Anti-Kell hemolytic disease of the newborn Rhesus c hemolytic disease of ... also known as Christmas disease) Hemophilia C Von Willebrand disease Disseminated intravascular coagulation Protein S ... Sickle cell disease Thalassemia Methemoglobinemia Anemias (lack of red blood cells or hemoglobin) Iron-deficiency anemia ...
... numerous case series have shown the feasibility of LS for a large variety of benign and malignant hematologic diseases. ... Splenectomy for malignant hematologic diseases. Splenectomy for malignant diseases mostly is performed for diagnosis or staging ... Laparoscopic splenectomy for benign and malignant hematologic diseases. Bertrand Millat, M.D. and Georges Decker, M.D. ... Decker G, Millat B, Guillon F, Atger J, Linon M. Laparoscopic splenectomy for benign and malignant hematologic diseases: 35 ...
Stem Cell Transplant for Hematologic Diseases (HIMSUM). The safety and scientific validity of this study is the responsibility ... Hematologic Malignancies. Interventions: Biological: Campath 1H. Drug: Fludarabine. Procedure: Stem Cell Transplant. Radiation ...
The COPII pathway and hematologic disease. Rami Khoriaty, Matthew P. Vasievich and David Ginsburg ... Multiple diseases, hematologic and nonhematologic, result from defects in the early secretory pathway. Congenital ... Defects in the ER export machinery have been reported to cause 2 hematologic diseases, combined deficiency of coagulation ... There is significant overlap between the clinical manifestations of CDAII and some other hematologic diseases. Therefore, a ...
... in the treatment of hematologic diseases and in solid tumors as monotherapy or in combination with other agents is an exciting ... The use of thalidomide (Thalomid) in the treatment of hematologic diseases and in solid tumors as monotherapy or in combination ... The use of thalidomide (Thalomid) in the treatment ofhematologic diseases and in solid tumors as monotherapy or in combination ... to determine the feasibilityof using thalidomide in a population of renal-cell carcinoma patients withprogressive disease, ...
This chapter presents the extragastric manifestations of H. pylori infection expressed through hematologic diseases; ... While H. pylori infection is asymptomatic in most infected individuals, it is intimately related to malignant diseases of the ... pylori infection and the development of diseases associated with cardiology, dermatology, endocrinology, obstetrics and ... stomach, such as gastric cancer and gastric MALT lymphoma, as well as benign diseases, for example chronic gastritis and ...
Splenectomy for Hematologic Disease: A 10 Year Review. Background: Laparoscopic splenectomy (LS) has been established as a safe ... Conclusion: LS is feasible for both benign and malignant hematologic disease. However, LS for spleens larger than 1 kg or 15 cm ... The purpose of this study was to review our teaching institutions experience with splenectomy for hematologic disease. ... hematologic diseases by a single surgeon. These cases were reviewed for their post-operative outcomes, with particular ...
... and discuss a potential role of vitamin D for treating hematologic disorders and modulating the immune system to improve the ... which may allow an avenue for improved treatment and support of patients suffering from hematologic disorders. In this review, ... The Role of Vitamin D in Hematologic Disease and Stem Cell Transplantation. Aric C. Hall * and Mark B. Juckett. ... Hall, A.C.; Juckett, M.B. The Role of Vitamin D in Hematologic Disease and Stem Cell Transplantation. Nutrients 2013, 5, 2206- ...
encoded search term (Dermatologic Manifestations of Hematologic Disease) and Dermatologic Manifestations of Hematologic Disease ... Dermatologic Manifestations of Hematologic Disease Updated: Jun 16, 2017 * Author: Saira J George, MD; Chief Editor: William D ... 28] According to the Cooperative Study of Sickle Cell Disease, approximately 25% of patients with sickle cell disease in the ... Cutaneous manifestations of systemic disease: sarcoidosis, GVHD, Behcets disease, and pyoderma gangrenosum. Dermatol Nurs. ...
should be added to the list of microorganisms causing invasive fungal disease in neutropenic patients with hematologic ... We report a lung-invasive fungal disease with possible cutaneous needle tract seeding in a patient with a febrile neutropenia ... Inonotosis in Patient with Hematologic Malignancy. Emerging Infectious Diseases. 2018;24(1):180-182. doi:10.3201/eid2401.171265 ... should be added to the list of microorganisms causing invasive fungal disease in neutropenic patients with hematologic ...
Centers for Disease Control and Prevention, * National Center for Emerging and Zoonotic Infectious Diseases (NCEZID). Office of ... Carbapenemase-producing Klebsiella pneumoniae and Hematologic Malignancies. Emerging Infectious Diseases. 2014;20(7):1235-1236 ... Carbapenemase-producing Klebsiella pneumoniae and Hematologic Malignancies. Emerging Infectious Diseases, 20(7), 1235-1236. ... Emerging Infectious Disease journal ISSN: 1080-6059 Note: Javascript is disabled or is not supported by your browser. For this ...
In hematologic diseases, such as sickle cell disease (SCD) and hemolytic uremic syndrome (HUS), pathological biophysical ... In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic ... In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic ... the model enabled quantitative investigation of how biophysical alterations in hematologic disease collectively lead to ...
Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease. The safety and ... Additional disease staging procedures and studies for other hematologic malignancies as clinically indicated. ... Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease ... Matched Bone Marrow and Kidney Transplantation for Multiple Myeloma or Other Hematologic Disorders With End Stage Renal Disease ...
Flow Cytometry, Hematologic Diseases Available as an add-on in conjunction with, or after, a Diagnostic/Prognostic Profile ... Flow Cytometry, Hematologic Diseases, Various - case dependent A tech-only 25-marker screening profile for peripheral blood ... Flow Cytometry, Hematologic Diseases, Various - case dependent A tech-only 20-marker screening profile for fresh tissue ... Chronic Myelogenous Leukemia (CML), Hematologic Diseases, Molecular The BCR-ABL MRDx® TFR Monitoring Test is a companion ...
Hematologic Diseases. Amyloidosis. Neoplasms by Histologic Type. Neoplasms. Hemostatic Disorders. Vascular Diseases. ... Immune System Diseases. Kidney Diseases. Urologic Diseases. Renal Insufficiency, Chronic. Renal Insufficiency. Proteostasis ... Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease. The safety and ... Additional disease staging procedures and studies for other hematologic malignancies as clinically indicated. ...
Viela Bio Enters Strategic Collaboration with Hansoh Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases ... and Hematologic Cancers in China - read this article along with other careers information, tips and advice on BioSpace ... "Viela is a leader in researching and developing breakthrough treatments for inflammation and autoimmune diseases. Together, we ... Strategic Collaboration with Hansoh Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases and Hematologic ...
Irradiation and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic ... Graft-Versus-Host Disease , Graft-Versus-Host Disease (GVHD) , Lymphoproliferative Disorder , MYELODYSPLASTIC SYNDROME , Non- ... Hodgkins Disease , Severe Aplastic Anemia , Chronic Myelomonocytic Leukemia in Remission , Bone marrow disorder , Acute ... Minimal Residual Disease , Multiple Myeloma , Preleukemia , Adult Acute Lymphoblastic Leukemia in Complete Remission , Lymphoma ...
Condition or disease Intervention/treatment Phase Hematologic Malignancies Graft-Versus-Host Disease Biological: Activated PTCy ... Graft vs Host Disease. Neoplasms. Immune System Diseases. Cyclophosphamide. Immunosuppressive Agents. Immunologic Factors. ... for patients with hematologic malignancies with bone marrow involvement of their relapsed disease. These MILs will be derived ... Time from day of PTCy-MILs infustion to progression/relapse of disease or death from any cause, whichever occurs first ...
Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges. In this webcast symposium, Gail J ... discusses the role of minimal residual disease testing in the treatment of patients with acute myeloid leukemia (AML). Dr. ... patient cases and data from recent clinical trials while emphasizing the challenges associated with minimal residual disease ( ...
Autoimmune and Inflammatory Diseases Curr Med Chem. 2016;23(12):1217-38. doi: 10.2174/0929867323666160318173706. ... Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, ... inflammatory and autoimmune diseases. At present the commercially available proteasome inhibitors Bortezomib and Carfilzomib, ... which have been validated in multiple myeloma and other diseases, appear to target both the constitutive and immunoproteasomes ...
disease.. - Determine the disease-free survival and long-term survival in patients treated with. this regimen.. - Determine the ... Chediak-Higashi disease. - X-linked lymphoproliferative disease. - Adenosine deaminase deficiency. - Purine nucleoside ... Patients are assigned to one of three conditioning regimens, depending on disease.. - Group A (malignant disease ): Patients ... Patients are stratified according to disease group. (malignant vs nonmalignant). Patients with malignant disease are further ...
... and fluoroscopy-guided subclavian vein catheterization in pediatric population with hematologic diseases. ... Children Fluoroscopy Hematologic disease Subclavian vein catheterization Ultrasound This is a preview of subscription content, ... Pang H, Chen Y, He X, Zeng Q, Ye P. Fluoroscopy-guided subclavian vein catheterization in 203 children with hematologic disease ... A randomized prospective study of subclavian vein catheterization in pediatric population with hematologic diseases was ...
In this study we aimed to evaluate the discriminative ability of hematologic, biochemical … ... Background As coronavirus disease 2019 (COVID-19) pandemic rages on, there is urgent need for identification of clinical and ... Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease ... compared survivors and non-survivors of the disease and were thus analyzed separately. Patients with severe and fatal disease ...
  • Gain insights into the critical limitations of immunotherapies, explore ways in which these therapies can be improved for widespread use in patients with hematologic malignancies and learn about the application of immunotherapies for the treatment of non-malignant hematologic diseases. (hematology.org)
  • Seventy-nine of these LS (9%) have been performed for various hematologic malignancies with or without splenomegaly. (nih.gov)
  • should be added to the list of microorganisms causing invasive fungal disease in neutropenic patients with hematologic malignancies. (cdc.gov)
  • Until a few years ago, the most frequent microbiologically documented cause of severe bloodstream infections among patients with hematologic malignancies was gram-positive bacteria ( 1 ). (cdc.gov)
  • However, over the years, gram-negative bacteria have become the main infectious cause of death among patients with hematologic malignancies, and rates of different phenotypes associated with antimicrobial drug resistance are increasing ( 2 ). (cdc.gov)
  • We reviewed records of all patients affected by hematologic malignancies who were admitted to the hospital hematology department from January 2009 through December 2012 and in whom a bloodstream infection caused by gram-negative bacteria developed. (cdc.gov)
  • Assess anti-tumor response rates in patients with hematologic malignancies [ Time Frame: Participants will be followed on an intention-to-treat basis, and data from all enrolled participants will be collected, irrespective of outcome, for the scheduled minimum follow-up period of 3 years. (clinicaltrials.gov)
  • Additional disease staging procedures and studies for other hematologic malignancies as clinically indicated. (clinicaltrials.gov)
  • This phase II trial studies how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant. (centerwatch.com)
  • This Phase 1 clinical study is designed to examine the safety and feasibility of using anti-CD3 /CD28 activated marrow infiltrating lymphocytes (MILs) as treatment of relapse after allogeneic hematopoietic cell transplantation (alloHCT) for patients with hematologic malignancies with bone marrow involvement of their relapsed disease. (clinicaltrials.gov)
  • Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes Derived From Patients With Bone Marrow Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide Graft-Versus-Host Disease Prophylaxis. (clinicaltrials.gov)
  • Recent studies demonstrated that the immunoproteasome function is not only limited to MHC class I presentation, but it is also implicated in a number of pathological disorders including hematological malignancies, inflammatory and autoimmune diseases. (nih.gov)
  • Determine the incidence and severity of acute and chronic graft-versus-host disease, complications (infection, veno-occlusive disease, interstitial pneumonitis), relapse, other malignancies, lymphoproliferative disorders, and posttransplantation myelodysplasia in patients treated with this regimen. (knowcancer.com)
  • BACKGROUND: Using data from the Healthcare Cost and Utilization Project 2004 Nationwide Inpatient Sample, we estimated inpatient resource utilization among patients with hematologic malignancies, with and without concomitant acute renal failure. (rti.org)
  • PATIENTS AND METHODS: We analyzed patients with hematologic malignancies (excluding Hodgkin disease), acute renal failure, and renal dialysis. (rti.org)
  • Subgroup analyses were performed on specific types of hematologic malignancies, with and without acute renal failure and with and without renal dialysis. (rti.org)
  • RESULTS: Among those with hematologic malignancies, acute renal failure, with and without concomitant renal dialysis, increases inpatient length of stay and costs. (rti.org)
  • CONCLUSION: Treatment of hematologic malignancies and concomitant acute renal failure and renal dialysis places an economic burden on the health care system. (rti.org)
  • Reducing the incidence of acute renal failure and concomitant renal dialysis with supportive care in patients with hematologic malignancies can reduce inpatient resource use. (rti.org)
  • BACKGROUND AND OBJECTIVES: Hepatitis C virus (HCV) infection is frequent among patients with hematologic malignancies and unapparent routes of infection may be important in this setting. (haematologica.org)
  • Activation of the RAS signal transduction cascade is a common feature in the molecular pathogenesis of hematologic malignancies. (eurekaselect.com)
  • This review provides a background on RAS signaling in hematologic malignancies and discusses opportunities to exploit aberrant cancer cell signaling in order to develop better treatment options for patients suffering from these diseases. (eurekaselect.com)
  • Patients with hematologic malignancies are at high risk for infectious complications. (endocrinologyadvisor.com)
  • Pulmonary alveolar proteinosis is a rare complication seen in patients with hematologic malignancies--usually acute and chronic myeloid leukemias and myelodysplastic syndrome. (endocrinologyadvisor.com)
  • Patients with hematologic malignancies often receive repeated transfusions with various blood products, thereby presenting an ongoing risk of TRALI. (endocrinologyadvisor.com)
  • HSCT is an important treatment option for select patients with hematologic malignancies or for solid tumors, where this procedure serves as a "rescue" therapy to restore immunologic and hematologic competence after myeloablative radiation and/or chemotherapy. (endocrinologyadvisor.com)
  • We also investigate how the presence of asthma and autoimmune diseases affects the risk of hematologic malignancies. (au.dk)
  • Providing a comprehensive overview on the significance of MRD in the evaluation, treatment and follow-up of hematologic malignancies, it will be of great value to hematologists, researchers interested in leukemias and lymphomas as well as laboratory technicians. (am-medicine.com)
  • In addition, treatment-related hematologic malignancies are reviewed. (naver.com)
  • Feb 27th, 2019 - Now in its 23rd year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies the practical tools to translate emerging data into the best therapy for patients with these tumors, personalize care based upon patient and tumor characteristics, and apply novel management strategies to thei. (allmedx.com)
  • These include hematologic malignancies (for example, Hodgkin's lymphoma, B and T cell lymphoma and multiple myeloma). (renalandurologynews.com)
  • Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft versus host disease). (centerwatch.com)
  • I. To determine the cumulative incidence of extensive chronic graft versus host disease (GVHD) at 1 year after transplantation utilizing the novel conditioning/GVHD prophylactic regimen for patients undergoing allogeneic hematopoietic cell transplantation, in patients who do not progress before day 100. (centerwatch.com)
  • These MILs will be derived from the bone marrow of the relapsed patient who had previously received post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis (PTCy-MILs). (clinicaltrials.gov)
  • These cells do not cause graft-versus-host disease (GVHD), and thus, autologous transplantation is associated with less morbidity and mortality than is allogeneic bone marrow transplant (BMT) and increases the age limit and the number of patients who can undergo the procedure. (renalandurologynews.com)
  • Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. (uniklinik-freiburg.de)
  • Bone marrow biopsy and aspirate for patients with hematologic malignancy and prior bone marrow involvement (pre-transplant, Day 100, 6 months, year 1, year 2). (clinicaltrials.gov)
  • GAITHERSBURG, Md. & SHANGHAI--( BUSINESS WIRE )-- Viela Bio, Inc. ("Viela") and Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma") today announced a collaboration focused on development and commercialization of inebilizumab - Viela's humanized anti-CD19 monoclonal antibody - in China for neuromyelitis optica spectrum disorder (NMOSD), as well as other potential inflammation/autoimmune and hematologic malignancy indications. (biospace.com)
  • This study describes our experience with E.coli as a pathogen in neutropenic patients with a hematologic malignancy, and addresses future directions of treatment for this patient population. (mjhid.org)
  • A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy. (clinicaltrials.gov)
  • Hematologic diseases, disorders of the blood and blood-forming organs, afflict millions of Americans. (nih.gov)
  • In addition to blood cell cancers, hematologic diseases include rare genetic disorders, anemia, conditions related to HIV, sickle cell disease, and complications from chemotherapy or transfusions. (nih.gov)
  • The other hematologic disorders were lymphoproliferative disorders: macroglobulinemia, chronic lymphocytic lymphoma, other lymphomas (including low-grade B-cell and diffuse large B-cell lymphoma), and cutaneous T-cell lymphoma. (medscape.com)
  • Hematologic diseases are disorders which primarily affect the blood & blood-forming organs. (wikipedia.org)
  • Hematologic diseases include rare genetic disorders, anemia, HIV, sickle cell disease & complications from chemotherapy or transfusions. (wikipedia.org)
  • These effects impact normal and dysfunctional hematopoietic and immune function, which may allow an avenue for improved treatment and support of patients suffering from hematologic disorders. (mdpi.com)
  • In this review, we will summarize the role of vitamin D in normal hematopoiesis, discuss ways in which vitamin D may improve outcomes, and discuss a potential role of vitamin D for treating hematologic disorders and modulating the immune system to improve the outcome of allogeneic stem cell transplant. (mdpi.com)
  • Hansoh Pharma is a leading biopharmaceutical company in China committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders, together with its 8,800 employees. (biospace.com)
  • Results from some clinical trials indicate that gene therapy can cure or improve many inherited or acquired hematologic disorders. (mhmedical.com)
  • Gene therapy is a promising treatment for several inherited or acquired hematologic disorders. (mhmedical.com)
  • Hemoglobinopathies are a group of blood disorders and diseases that affect the red blood cells. (fortismumbai.com)
  • In this report, we present cases of two hematologic disorders found in trauma patients: autoimmune hemolytic anemia induced by systemic lupus erythematosus and myelodysplastic syndrome. (jtraumainj.org)
  • However, it is difficult to distinguish between hematologic abnormalities associated with trauma and other hematologic disorders because both categories of conditions show similar hematologic abnormalities, and the ability to take a past medical history is limited in trauma patients. (jtraumainj.org)
  • As undiagnosed hematologic disorders in trauma patients could lead to delays in the correct diagnosis and improper treatment, physicians at a trauma center should always consider the possibility of other chronic diseases when encountering atypical and prolonged hematologic dysfunction. (jtraumainj.org)
  • DNA copy number, structural rearrangements, or altered microRNA/mRNA expression that are important for the initiation, progression, or treatment response of hematologic disorders. (bioportfolio.com)
  • Hemic diseases include disorders involving the formed elements (e.g. (bioportfolio.com)
  • lymphatic diseases include disorders relating to lymph, lymph nodes, and lymphocytes. (bioportfolio.com)
  • It provides an overview of the interface between epidemiology and molecular biology (Chapter 6) and discusses issues of surveillance in birth defects and genetic disorders ( Chapter 7 ), with a focus on hematologic diseases ( Chapter 8 ). (cdc.gov)
  • Autologous hematopoietic cell transplantation (HCT) is the intravenous infusion of hematopoietic stem and progenitor cells designed to re-establish marrow and immune function in patients with a variety of acquired malignant disorders, who are being treated with high dose chemotherapy or chemoradiotherapy to treat the disease. (renalandurologynews.com)
  • Testing for hematologic disorders and complications. (biomedsearch.com)
  • The clinical laboratory plays an essential role in the evaluation of these disorders by way of the use of various hematologic, biochemical, serologic, cytometric, and molecular genetics methods. (biomedsearch.com)
  • Analysis of fetal free DNA in maternal plasma holds the promise for rapid, ultrasensitive, and noninvasive detection of many fetal hematologic disorders. (biomedsearch.com)
  • Autoimmune diseases are chronic disorders that have been difficult, and often impossible, to cure. (itmonline.org)
  • overall, women are about 3 times as likely as men to suffer from autoimmune disorders (however, in some disorders, such as MS, men appear to have a more severe disease pattern). (itmonline.org)
  • A greater number of tests that can suggest or confirm presence of an autoimmune disease have become available so that it is now easier to make a diagnosis than ever before, but some disorders suspected of being autoimmune diseases still lack reliable tests, especially for their early stages. (itmonline.org)
  • For questions about the 2022 ASH Summit on Immunotherapies for Hematologic Diseases, please contact ASH Scientific Affairs Manager Alice Kuaban at [email protected] . (hematology.org)
  • The 2018 ASH Summit on Emerging Immunotherapies for Hematologic Diseases meeting featured an exhibition of products and services in the areas of hematology and blood transfusion. (hematology.org)
  • EAST HANOVER, N.J. , Nov. 28, 2012 /PRNewswire/ -- Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases. (sys-con.com)
  • Combining essential hematology content with the diagnostic features of an atlas, Veterinary Hematology: A Diagnostic Guide and Color Atlas delivers all the information you need to accurately assess and diagnose the blood diseases of common domestic animals - including dogs, cats, horses, cattle, sheep, goats, pigs, and llamas. (helsinki.fi)
  • Hematology is the branch of medicine concerned with the study, diagnosis, treatment, and prevention of diseases related to the blood. (vitalim.ca)
  • The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by Mattioli 1885, Fidenza, Italy. (mjhid.org)
  • The 2018 ASH Summit on Emerging Immunotherapies for Hematologic Diseases examined preclinical and clinical factors influencing the effective development, regulation, and implementation of immunotherapies for hematologic diseases. (hematology.org)
  • Clinical experience with thalidomide has also includedobservation of improvement in patients with prostate cancer and apparentresponses in patients with metastatic disease refractory to chemotherapy. (cancernetwork.com)
  • These experiments establish the versatility and clinical relevance of our microvasculature-on-a-chip model as a biophysical assay of hematologic pathophysiology as well as a drug discovery platform. (jci.org)
  • Viela Bio, headquartered in Gaithersburg, Maryland, is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease. (biospace.com)
  • Clinical responses (complete remissions, partial remissions, stable disease) as measured by criteria specific for the particular disease type. (clinicaltrials.gov)
  • In this webcast symposium, Gail J. Roboz, MD, professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York City, discusses the role of minimal residual disease testing in the treatment of patients with acute myeloid leukemia (AML). (thedoctorschannel.com)
  • Dr. Roboz shares patient cases and data from recent clinical trials while emphasizing the challenges associated with minimal residual disease (MRD) detection in acute myeloid leukemia (AML) patients. (thedoctorschannel.com)
  • Background As coronavirus disease 2019 (COVID-19) pandemic rages on, there is urgent need for identification of clinical and laboratory predictors for progression towards severe and fatal forms of this illness. (nih.gov)
  • Clinical, hematologic and serologic surveillance of all infected patients were part of the subsequent follow-up study which started in September 1998 and was completed in December 2001. (haematologica.org)
  • Many clinical trials have involved gene therapy for patients with various gene-deficient hematologic diseases, such as severe combined immunodeficiency, hemophilia, Wiskott-Aldrich syndrome, chronic granulomatous disease, aplastic anemia, hemoglobinopathies, HIV infection, and leukemia. (mhmedical.com)
  • Despite advances in antiretroviral therapy and in the treatment and prevention of opportunistic infections, oncological and consequent hematologic complications of human immunodeficiency virus (HIV) infection continue to occur and are of significant clinical importance. (oup.com)
  • Within malignant hematologic diseases research, we focus on the role of patient-related factors, such as comorbidity and socioeconomic status, and clinical factors, such as the presence of anemia, in relation to treatment and overall survival. (au.dk)
  • Although hematologic toxicity was not directly associated with clinical outcome in this analysis, use of hematopoietic growth factors was associated with an increased sustained virologic and/or histologic response. (oup.com)
  • Here, we aimed to investigate the clinical characteristics of SM bacteremia and to identify the risk factors of hemorrhagic pneumonia caused by SM in patients with hematologic diseases. (researchsquare.com)
  • The clinical records of 55 patients diagnosed with hematologic diseases and SM bacteremia were retrospectively reviewed. (researchsquare.com)
  • Persistent abnormalities in the complete blood count, however, require clinical suspicion of other hematologic diseases to minimize improper transfusions and to improve outcomes, including mortality. (jtraumainj.org)
  • Physicians at trauma centers should be familiar with the clinical characteristics of hematologic diseases and should consider these diseases in trauma patients. (jtraumainj.org)
  • Giles FJ, Albitar M. Plasma-based testing as a new paradigm for clinical testing in hematologic diseases. (exosome-rna.com)
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 47 (9). (fhcrc.org)
  • Feb 4th, 2019 - Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement inhibitor, APL-2, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of autoimmune hemolytic an. (allmedx.com)
  • Clinical, hematologic, and biochemical findings in cattle infected with lumpy skin disease during an outbreak in southwest Iran. (bioportfolio.com)
  • This study was performed to determine the clinical, hematologic, and biochemical findings in animals affected with lumpy skin disease (LSD) in southwest Iran. (bioportfolio.com)
  • Although treatment is indicated in hedgehogs with clinical signs of disease, owners should be advised of the zoonotic potential and the risks of creating antibiotic resistance. (merckvetmanual.com)
  • The Institute also supports government scientists who conduct basic, translational, and clinical research across a broad spectrum of research topics and serious, chronic diseases and conditions related to the Institute's mission. (nih.gov)
  • The new Institute incorporated the laboratories of the Experimental Biology and Medicine Institute and expanded to include clinical investigation in rheumatic diseases, diabetes, and a number of metabolic, endocrine, and gastrointestinal diseases. (nih.gov)
  • This is an observational cohort study to follow vitamin D levels over time in patients with sickle cell disease receiving doses of vitamin D as part of their clinical care for vitamin D deficiency. (clinicaltrials.gov)
  • In hematologic diseases, such as sickle cell disease (SCD) and hemolytic uremic syndrome (HUS), pathological biophysical interactions among blood cells, endothelial cells, and soluble factors lead to microvascular occlusion and thrombosis. (jci.org)
  • These genetic defects produce abnormal haemoglobin and anaemia like sickle-cell disease, congenital dyserythropoietic anemia, etc. (fortismumbai.com)
  • However, splenectomy, even if with different modalities including laparoscopic splenectomy and partial splenectomy, continue to be a current surgical practice both in nonmalignant hematologic diseases, such as Immune Thrombocytopenic Purpura (ITP), Autoimmune Hemolytic Anemia (AIHA), Congenital Hemolytic Anemia such as Spherocytosis, Sickle Cell Anemia and Thalassemia and Malignant Hematological Disease, such as lymphoma. (mjhid.org)
  • [1] Risk factors include a family history, prior blood clots in the lungs , HIV/AIDS , sickle cell disease , cocaine use, chronic obstructive pulmonary disease , sleep apnea , living at high altitudes , and problems with the mitral valve . (wikipedia.org)
  • Hydroxyurea improves hematologic parameters for children with sickle cell disease (SCD), but its long-term efficacy at maximum tolerated dose (MTD) has not been determined. (unboundmedicine.com)
  • There are approximately 90,000 individuals in the United States with sickle cell disease (SCD). (clinicaltrials.gov)
  • Studies have shown that up to 98 percent of patients with Sickle Cell Disease have a vitamin D deficiency, defined as a 25-hydroxyvitamin D level (25(OH)D) less than or equal to 20 ng/mL. (clinicaltrials.gov)
  • Thus, the main purpose of this study is to find the amount of nutritional vitamin D that needs to be taken by patients with sickle cell disease in order to correct vitamin D deficiency. (clinicaltrials.gov)
  • It is estimated that more than 600,000 bone marrow biopsies are performed annually in the U.S. to diagnose and monitor patients with various hematologic cancers. (exosome-rna.com)
  • In this study we aimed to evaluate the discriminative ability of hematologic, biochemical and immunologic biomarkers in patients with and without the severe or fatal forms of COVID-19. (nih.gov)
  • Hematologic and serum biochemical reference ranges and an assessment of exposure to infectious diseases prior to translocation of the threatened western ringtail possum (Pseudocheirus occidentalis). (semanticscholar.org)
  • Hematologic and serum biochemical reference values for free-ranging northern hairy-nosed wombats. (semanticscholar.org)
  • Hematologic and biochemical testing are useful to screen for concurrent problems and to monitor the effects of therapeutic agents. (merckvetmanual.com)
  • Thirty of them were laparoscopic staging procedures for Hodgkin's disease (HD) whereas chronic lymphocytic leukemia, non-Hodkin lymphomas and a variety of other lympho- or myeloproliferative diseases have only sporadically been approached laparoscopically. (nih.gov)
  • While H. pylori infection is asymptomatic in most infected individuals, it is intimately related to malignant diseases of the stomach, such as gastric cancer and gastric MALT lymphoma, as well as benign diseases, for example chronic gastritis and duodenal and gastric peptic ulcers. (intechopen.com)
  • Filamentous Basidiomycetes molds are ubiquitous and able to colonize in patients with chronic pulmonary disease. (cdc.gov)
  • In chronic cold agglutinin disease, the patient is more symptomatic during the colder months. (medscape.com)
  • Primary cold agglutinin disease is chronic and occurs after the fifth decade of life, with a peak incidence in the seventh and eighth decades. (medscape.com)
  • Monoclonal secondary disease is usually chronic, occurring in adults. (medscape.com)
  • We also report the association between BDV in the thymus with the lack, or loss, of encephalitis in neonatally inoculated rats or adult-inoculated rats during the chronic stage of disease. (elsevier.com)
  • This list of sicknesses, medical conditions, and chronic or non-chronic diseases treated with methylprednisolone is in alphabetical order, and you can click any ailment to read more about it. (ranker.com)
  • Human genetic variation is associated with many, if not all, human diseases and disabilities, including the common chronic diseases of major public health impact. (cdc.gov)
  • Sjögren's syndrome is a chronic, slowly progressing inability to secrete saliva and tears, and is usually a late-onset disease. (itmonline.org)
  • Background: Laparoscopic splenectomy (LS) has been established as a safe and effective alternative to open splenectomy (OS) for the treatment of appropriate patients with hematologic disease. (sages.org)
  • This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide (CY), fludarabine phosphate (FLU), and total-body irradiation (TBI) works in treating patients with hematologic disease. (sparkcures.com)
  • Emerging Infectious Diseases , 20 (7), 1235-1236. (cdc.gov)
  • This preprint is under consideration at BMC Infectious Diseases . (researchsquare.com)
  • This section further deals with public health assessment in the genetics of cancer ( Chapter 9 ), infectious diseases ( Chapter 10 ), and occupational health ( Chapter 11 ). (cdc.gov)
  • Alimentary candidiasis ( Candida albicans ) and cryptosporidiosis are other reported infectious diseases. (merckvetmanual.com)
  • Infectious diseases and antibiotic therapy. (slideshare.net)
  • Prenatal testing for infectious disease. (biomedsearch.com)
  • in addition many of the diseases in this category appear to have a viral or other infectious agent as a trigger for onset of the autoimmune status. (itmonline.org)
  • Section Chief, Division of Infectious Diseases and Tropical Medicine - Moffitt Cancer Center, Tampa FL Professor of Medicine, United States . (mjhid.org)
  • He is a Professor of Medicine and currently the Section Chief, Division of Infectious Diseases and Tropical Medicine and Senior Member of the Blood & Marrow Transplant department at Moffitt Cancer Center, Tampa, FL. (mjhid.org)
  • Thought you might appreciate this item(s) I saw at The Pediatric Infectious Disease Journal. (lww.com)
  • Information thus obtained would allow subsequent submission of R01 applications focusing on research problems relevant to the study of hematologic diseases and their complications. (nih.gov)
  • Pulmonary complications of hematologic diseases like leukemia or after bone marrow or hematopoietic stem cell transplantations (HSCT) are common. (endocrinologyadvisor.com)
  • INTRODUCTION: This study aims to document and analyze the central venous catheter (CVC)-related complications in children with hematological diseases who were treated within a single institution. (tjh.com.tr)
  • RBC transfusion is indicated in severe, acute disease. (medscape.com)
  • Acute pancreatitis (AP) is an emergency disease within the field of internal diseases. (mattioli1885journals.com)
  • The use of thalidomide (Thalomid) in the treatment of hematologic diseases and in solid tumors as monotherapy or in combination with other agents is an exciting development in cancer therapy. (cancernetwork.com)
  • The use of thalidomide (Thalomid) in the treatment ofhematologic diseases and in solid tumors as monotherapy or in combination withother agents is an exciting development in cancer therapy. (cancernetwork.com)
  • HCT also is used in the support of patients undergoing high-dose chemotherapy for the treatment of certain solid tumors for whom hematologic toxicity would otherwise limit drug administration (germ cell, soft-tissue sarcomas, and neuroblastoma). (renalandurologynews.com)
  • From a practical standpoint, hematological associations with H. pylori infection can be arbitrarily divided into two groups: (1) hematological diseases with sufficient scientific evidence to be recognized by the consensus and guidelines for the management of H. pylori among the indications of study and eradication and (2) hematological diseases where there is suspicion, with greater or lesser scientific evidence, of an association with H. pylori infection. (intechopen.com)
  • Indications of splenectomy for hematologic diseases have been reducing in the last few years, due to improved diagnostic and therapeutic tools. (mjhid.org)
  • Moreover, the impact of this infection on the outcome of the hematologic disease needs to be better defined. (haematologica.org)
  • HCV infection did not influence the course of the underlying disease or the use of specific therapies. (haematologica.org)
  • As regards the impact of HCV infection on the outcome of the hematologic diseases, changes in the scheduled therapy, including stem cell transplantation, were not required. (haematologica.org)
  • Background .This study investigates whether dose modifications for adverse hematologic effects or the use of hematopoietic growth factors influenced the outcome of therapy for hepatitis C virus (HCV) infection in patients who were coinfected with HCV and human immunodeficiency virus (HIV) and who were participants in a randomized, controlled trial. (oup.com)
  • Among 85 patients who were diagnosed with splenomegaly through abdominal palpation or ultrasound at any point after resettlement, 53 had some hematologic abnormality (leukopenia, anemia, or thrombocytopenia), 16 had evidence of current or recent malaria infection, and eight had evidence of schistosomiasis. (cdc.gov)
  • Carbone, K. M. / Hematologic consequences of Borna disease virus infection of rat bone marrow and thymus stromal cells . (elsevier.com)
  • Special Topic Issue: Acta Haematologica 2004, Vol. 112, No. 1-2 Detection of minimal residual disease (MRD) is increasingly used in the management of leukemia patients. (am-medicine.com)
  • Since the first laparoscopic splenectomy (LS) performed by Delaître in 1991, numerous case series have shown the feasibility of LS for a large variety of benign and malignant hematologic diseases. (nih.gov)
  • Although there has not yet been a single prospective randomized study to support any advantage of laparoscopic over open splenectomy (OS), the laparoscopic approach has rapidly become very popular and has even been proposed as "gold standard" for splenectomy in hematologic diseases with normal size or moderately enlarged spleens. (nih.gov)
  • The purpose of this study was to review our teaching institution's experience with splenectomy for hematologic disease. (sages.org)
  • Splenectomy, while often necessary in otherwise healthy patients after major trauma, find its primary indication for patients with an underlying malignant or nonmalignant hematologic diseases. (mjhid.org)
  • In high-income countries, there is a clear decrease over calendar time in the incidence of all indication splenectomy except nonmalignant hematologic diseases. (mjhid.org)
  • The underlying disease is the most important factor in determining the frequency and severity of infections.So, splenectomy for malignant diseases has the major risk of infections. (mjhid.org)
  • Aim: The role of laparoscopic splenectomy in the treatment of hematological diseases is still controversial. (elsevier.com)
  • The aim of this study was to assess whether the benign or malignant nature of hematological diseases may influence the outcome of laparoscopic splenectomy. (elsevier.com)
  • Patients and methods: Between August 1997 and March 2002, 63 unselected patients with hematologic diseases underwent a laparoscopic splenectomy. (elsevier.com)
  • Conclusions: The results of the study showed that: a) the nature of the disease does not influence the outcome of laparoscopic splenectomy, b) the size of the spleen might increase the risk of conversion, but it is no longer a contraindication to laparoscopic splenectomy, and c) laparoscopic splenectomy can be effectively performed in the treatment of malignant hematologic diseases. (elsevier.com)
  • This pilot trial offers the unique opportunity for both the treatment of multiple myeloma or other hematologic disorder for which hematopoietic stem cell transplantation would be ordinarily indicated and the reversal of end-stage renal failure, while avoiding the risks associated with long-term standard anti-rejection therapy used in renal transplantation. (aamds.org)
  • Doses were modified for a number of adverse effects (including hematologic toxicity), and hematopoietic. (oup.com)
  • and the limited ability to use autologous stem cells to treat patients not in remission or with inherited nonmalignant lympho-hematopoietic diseases ( Table I ). (renalandurologynews.com)
  • Gain insight on the use of combination therapies in the treatment of hematologic diseases. (hematology.org)
  • Develop a better understanding of the use of cell-based therapies for the treatment on non-malignant and virus-associated hematologic diseases. (hematology.org)
  • Splenectomies may be performed for diagnosis, staging or treatment of a variety of benign or malignant hematologic diseases. (nih.gov)
  • Screening for variants in TPMT did not reduce the proportions of patients with hematologic ADRs during thiopurine treatment for IBD. (snfge.org)
  • However, there was a 10-fold reduction in hematologic ADRs among variant carriers who were identified and received a dose reduction, compared with variant carriers who did not, without differences in treatment efficacy. (snfge.org)
  • The best treatment of cold agglutinin disease is avoidance of cold temperatures. (tripdatabase.com)
  • RATIONALE: Evaluating patients who have skin diseases may help doctors plan more effective treatment and follow-up for skin diseases and systemic diseases that show up in the skin. (bioportfolio.com)
  • [7] Treatment depends on the type of disease. (wikipedia.org)
  • Some patients relay experiences of pursuing medical diagnosis and treatment for a decade before getting a definitive disease name. (itmonline.org)
  • D. Anderson Cancer Center, investigators looked to determine the feasibilityof using thalidomide in a population of renal-cell carcinoma patients withprogressive disease, despite chemotherapy and immunotherapy. (cancernetwork.com)
  • A hematologic cancer and central nervous system neoplasm that is located_in the central nervous system. (zfin.org)
  • Congenital dyserythropoietic anemia type II (CDAII) and combined deficiency of coagulation factors V and VIII (F5F8D) are the 2 known hematologic diseases that result from defects in the endoplasmic reticulum (ER)-to-Golgi transport system. (bloodjournal.org)
  • Defects in the ER export machinery have been reported to cause 2 hematologic diseases, combined deficiency of coagulation factors V (FV) and VIII (FVIII) (F5F8D) and congenital dyserythropoietic anemia type II (CDAII). (bloodjournal.org)
  • The co-occurrence of pregnancy and a blood disease (HEMATOLOGIC DISEASES) which involves BLOOD CELLS or COAGULATION FACTORS. (bioportfolio.com)
  • See below for information on the 2018 ASH Summit on Emerging Immunotherapies for Hematologic Diseases. (hematology.org)
  • To compare the ultrasound- and fluoroscopy-guided subclavian vein catheterization in pediatric population with hematologic diseases. (springer.com)
  • A randomized prospective study of subclavian vein catheterization in pediatric population with hematologic diseases was performed. (springer.com)
  • Long-term hydroxyurea therapy at MTD is well tolerated by pediatric patients with SCD and has sustained hematologic efficacy with apparent long-term safety. (unboundmedicine.com)
  • We report two rare cases of hematologic diseases diagnosed in patients with serious trauma: systemic lupus erythematosus (SLE)-induced autoimmune hemolytic anemia (AIHA) and myelodysplastic syndrome (MDS). (jtraumainj.org)
  • Systemic involvement in autoimmune diseases is often unclear and organ changes are confounding, thus making it difficult to have an early accurate diagnosis. (bioportfolio.com)
  • abstract = "Borne disease virus (BDV) was previously believed to have a strict tropism for the nervous system. (elsevier.com)
  • Methods: Between 1996 and 2005 a total of 101 consecutive splenectomies were performed for both benign (53) and malignant (48) hematologic diseases by a single surgeon. (sages.org)
  • These diseases and their molecular pathogenesis are the focus of this review. (bloodjournal.org)
  • 13 In this review, we focus on the 2 hematologic diseases resulting from defects in the early secretory pathway, F5F8D and CDAII, and their molecular pathogenesis. (bloodjournal.org)
  • PUBLIC HEALTH RELEVANCE: Programmed cell death or apoptosis regulates the critical balance between cellular life and death and, when deregulated, contributes to the pathogenesis of a wide variety of hematologic diseases characterized by too many or too few blood cells. (elsevier.com)
  • Aug 4th, 2017 - Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. (allmedx.com)
  • Cold agglutinin disease is a rare form of autoimmune hemolytic anemia caused by cold-reacting autoantibodies. (medscape.com)
  • Immune-mediated diseases include include hemolytic anemia (AIHA, IMHA) and/or thrombocytopenia (low platelet count, IMTP). (animalwellnessmagazine.com)
  • Autoimmune hemolytic anemia refers to both cold agglutinin disease and warm autoimmune hemolytic anemia, which affect a combined 40,000 people in the United States and Europe. (allmedx.com)
  • The disease is characterised by large lysosome vesicles in phagocytes (neutrophils), which thus have poor bactericidal function, leading to susceptibility to infections, abnormalities in nuclear structure of leukocytes, anemia , and hepatomegaly . (wikipedia.org)
  • Musculoskeletal system, osteoarticular and inflammatory diseases. (slideshare.net)
  • Metabolic diseases. (slideshare.net)
  • August 15, 1950 -President Harry S. Truman signed the Omnibus Medical Research Act into law, establishing the National Institute of Arthritis and Metabolic Diseases (NIAMD) in the U.S. Public Health Service. (nih.gov)
  • November 15, 1950 -The National Advisory Arthritis and Metabolic Diseases Council held its first meeting and recommended approval of NIAMD's first grants. (nih.gov)
  • Juckett, M.B. The Role of Vitamin D in Hematologic Disease and Stem Cell Transplantation. (mdpi.com)
  • Forty months after the outbreak, five patients are alive (one after autologous and one after allogeneic stem cell transplantation), while eight have died, seven of hematologic disease, and one of cardiac failure. (haematologica.org)
  • Severe cold agglutinin disease and cryoglobulinemia secondary to a monoclonal anti-Pr2 IgM lambda cryoagglutinin. (medscape.com)
  • Viela recently presented positive results from a pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD) - a rare autoimmune disease characterized by unpredictable attacks that often lead to severe, irreparable disability including blindness and paralysis. (biospace.com)
  • While 18 studies (n = 2984) compared laboratory findings between patients with severe and non-severe COVID-19, the other three (n = 393) compared survivors and non-survivors of the disease and were thus analyzed separately. (nih.gov)
  • Patients with severe and fatal disease had significantly increased white blood cell (WBC) count, and decreased lymphocyte and platelet counts compared to non-severe disease and survivors. (nih.gov)
  • Interleukins 6 (IL-6) and 10 (IL-10) and serum ferritin were strong discriminators for severe disease. (nih.gov)
  • Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy (2000) Colombel Jean-frédéric et al. (naver.com)
  • The Hematologic Diseases Information Service is a part of the NIDDK's Division of Kidney, Urologic, and Hematologic Diseases. (wikipedia.org)
  • and kidney, urologic, and hematologic diseases, to improve people's health and quality of life. (nih.gov)
  • Centers for Disease Control and Prevention. (cdc.gov)
  • Saving Lives, Protecting People Centers for Disease Control and Prevention. (cdc.gov)
  • Standard bone marrow transplantation is associated with prohibitive toxicities in patients with end stage renal disease, and is generally not considered an option for those patients. (clinicaltrials.gov)
  • A less toxic bone marrow transplantation protocol, utilizing low dose total body irradiation and anti-thymocyte globulin, combined with renal transplantation, could provide an opportunity for cure of the myeloma or amyloidosis and correction of end stage renal disease. (clinicaltrials.gov)
  • Hematologic diseases comprise a heterogeneous group of benign and malignant diseases originating from the cells of the bone marrow and the lymphatic system, which contributes substantially to global mortality and morbidity. (au.dk)
  • Patients were divided into two groups according to the benign (Group A, 38 patients) or malignant (Group B, 25 patients) nature of the hematological diseases. (elsevier.com)
  • Because major trauma is often life-threatening, and hematologic abnormalities are multi-factorial and transient, major blood loss is usually suspected to be the primary cause of these abnormalities, and much time and cost may be spent attempting to identify a focus of hemorrhage that might or might not actually exist. (jtraumainj.org)
  • Epidemiology of hematologic diseases concerns the risk and prognosis of both benign and malignant hematologic diseases. (au.dk)

No images available that match "hematologic diseases"